<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app43.us.archive.org';v.server_ms=358;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10350?contentType=xml', '20160930212259')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20160930212259/https://www.guideline.gov/summaries/downloadcontent/ngc-10350?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20160930212259/https://www.guideline.gov/summaries/downloadcontent/ngc-10350?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10350?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20160930212259" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap">Aug</td>
		  <td class="c" id="displayMonthEl" title="You are here: 21:22:59 Sep 30, 2016">SEP</td>
		  <td class="f" nowrap="nowrap">Oct</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_prv_off.png" alt="Previous capture" width="14" height="16" border="0" /></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 21:22:59 Sep 30, 2016">30</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap">2015</td>
		  <td class="c" id="displayYearEl" title="You are here: 21:22:59 Sep 30, 2016">2016</td>
		  <td class="f" nowrap="nowrap">2017</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20160930212259*/https://www.guideline.gov/summaries/downloadcontent/ngc-10350?contentType=xml" title="See a list of every capture for this URL">1 capture</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10350?contentType=xml","2016-09-30",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>National Institute for Health and Care Excellence. Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer. London (UK): National Institute for Health and Care Excellence; 2014 Apr. 45 p.&amp;nbsp;(Technology appraisal guidance; no. 309).&amp;nbsp;</td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Pemetrexed is not recommended for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in people whose disease has not progressed immediately following induction therapy with pemetrexed and cisplatin.</p>
<p>People currently receiving treatment initiated within the National Health Service (NHS) with pemetrexed that is not recommended for them by the National Institute for Health and Care Excellence (NICE) in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Non-squamous non-small-cell lung cancer</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Assessment of Therapeutic Effectiveness"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Oncology"/>
      <fieldvalue value="Pulmonary Medicine"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To assess the clinical effectiveness and cost-effectiveness of pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Patients with locally advanced or metastatic (stage IIIB/IV) non-squamous non-small-cell lung cancer whose disease has not progressed immediately following first-line induction chemotherapy with pemetrexed and cisplatin</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Pemetrexed maintenance treatment</p></div>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Clinical effectiveness
    <ul style=&quot;list-style-type: disc;&quot;>
        <li>Overall survival (OS) </li>
        <li>Progression-free survival (PFS) </li>
        <li>Response rates </li>
        <li>Adverse effects of treatment (according to grade) </li>
        <li>Health-related quality of life (QoL) </li>
    </ul>
    </li>
    <li>Cost-effectiveness </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Note from the National Guideline Clearinghouse (NGC)</strong>: The National Institute for Health and Care Excellence (NICE) commissioned an independent academic centre to perform an assessment of the manufacturer's submission on the technology considered in this appraisal and prepare an Evidence Review Group (ERG) report. The ERG report for this technology appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG) (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Clinical Effectiveness</span></strong></p>
<p><strong>Critique of the Methods of Review(s)</strong></p>
<p><em>Searches and Inclusion Criteria</em></p>
<p>A systematic literature search was conducted to identify relevant Phase 3, randomised controlled trials (RCTs) of pemetrexed as maintenance treatment in people with advanced non-small-cell lung cancer (NSCLC). Key databases were searched, including Ovid Medline, Medline (R) In-Process and EMBASE. The Evidence Based Medicine Reviews database was used to search the Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials and the Cochrane Methodology Register as well as American College of Physicians (ACP) Journal Club, Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment and National Health Service (NHS) Evaluation database. Other databases searched were Biosys Previews and Current Contents. Searches of the American Society of Clinical Oncology website and internal Eli Lilly databases were also undertaken. All searches were conducted up to 25th July 2012. The ERG considers the range of databases included in the search to be thorough. Appropriate search strategies and inclusion criteria were utilised by the manufacturer.</p>
<p>The ERG has conducted its own searches and is confident that the PARAMOUNT trial, as identified by the manufacturer is the only Phase 3 RCT relevant to the decision problem.</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Cost-effectiveness</span></strong></p>
<p><strong>ERG Comment of Manufacturer's Review of Cost-effectiveness</strong></p>
<p>The manufacturer's search was designed to identify studies that evaluated the cost-effectiveness of maintenance treatments for patients with locally advanced or metastatic NSCLC. The search strategy was designed to inform the methodological approach for the economic evaluation and to identify data sources for relevant resources and health effects.</p>
<p>The literature search was performed on 4 February 2011 using National Health Service (NHS) Economic Evaluation Database (NHS EED) and on 7 February 2011 using MEDLINE and EMBASE. Subsequent searches were repeated on 5 October 2011 and 10 September 2012 to update the results. The search strategies used by the manufacturer are provided in the manufacturer's submission (MS).</p>
<p>Hand-searching of retrieved articles and appraisals conducted by NICE was also undertaken by the manufacturer.</p>
<p><em>Inclusion/Exclusion Criteria</em></p>
<p>The inclusion and exclusion criteria used by the manufacturer are summarised below.</p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Inclusion/Exclusion Criteria&quot;>
    <thead>
        <tr>
            <th valign=&quot;top&quot;>Parameter</th>
            <th valign=&quot;top&quot;>Inclusion Criteria</th>
            <th valign=&quot;top&quot;>Exclusion Criteria</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td valign=&quot;top&quot;>Population</td>
            <td valign=&quot;top&quot;>Non-small-cell lung cancer (NSCLC) stage IIIB-IV</td>
            <td valign=&quot;top&quot;>Study not in the population of interest</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Line of therapy</td>
            <td valign=&quot;top&quot;>Maintenance treatment</td>
            <td valign=&quot;top&quot;>Second-line therapy</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Study design</td>
            <td valign=&quot;top&quot;>Full economic evaluation (an evaluation of both costs and benefits)</td>
            <td valign=&quot;top&quot;>Partial evaluation, cost minimisation, review</td>
        </tr>
        <tr>
            <td valign=&quot;top&quot;>Other</td>
            <td valign=&quot;top&quot;>Study findings generalisable to the UK population</td>
            <td valign=&quot;top&quot;>Duplicates</td>
        </tr>
    </tbody>
</table></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Clinical Effectiveness</strong></p>
<p>One randomised controlled trial, the PARAMOUNT trial, was identified by the manufacturer.</p>
<p><strong>Cost-effectiveness</strong></p>
<p>Two studies were identified.</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Note from the National Guideline Clearinghouse (NGC)</strong>: The National Institute for Health and Care Excellence (NICE) commissioned an independent academic centre to perform an assessment of the manufacturer's submission on the technology considered in this appraisal and prepare an Evidence Review Group (ERG) report. The ERG report for this technology appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG) (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Clinical Effectiveness</span></strong></p>
<p><strong>Critique of the Methods of Review(s)</strong></p>
<p><em>PARAMOUNT Quality and Validity Assessment</em></p>
<p>The manufacturer's quality assessment of the PARAMOUNT trial demonstrates that the trial was well designed with robust methods of randomisation and appropriate blinding. The ERG notes that the primary endpoint was progression-free survival (PFS), but the trial was also powered for overall survival (OS) and that quality of life (QoL) was assessed using the EuroQol 5D (EQ-5D) utility score.</p>
<p>As the trial population was predominantly European, including six centres in the United Kingdom (UK), the results of the trial are considered by the ERG to be applicable to the clinical population in England and Wales, within the limits of the trial population.</p>
<p>Patients were recruited from 83 centres in 16 countries (Australia, Belgium, Canada, Finland, France, Germany, Greece, India, Italy, Netherlands, Poland, Portugal, Romania, Spain, Turkey and the UK). For the results of a trial with so many centres to be meaningfully interpreted, the manner in which the protocol is implemented should be clear and similar across all centres. This is because with so many investigators in different countries, general clinical practice will always be an issue and the results of a trial can only be generalisable if it is executed efficiently. The issue of data quality assurance is addressed in the clinical study report (CSR). It is stated that a number of quality control safeguards were put into place, including, but not limited to, instructional material provided to study sites, investigator training sessions, periodic visits to study sites, contact maintained with study sites, use of standard computer edits to detect errors in data collection. Evidence of study monitoring is provided in the CSR where it is reported that during routine site monitoring, Eli Lilly identified 17 events described as 'extraordinary', 'serious and/or persistent issues' that would not have been picked up from the electronic reporting forms. Once identified, the CSR states that each issue was addressed and documented.</p>
<p>According to the CSR, a total of 69 (19.2%) patients randomised to pemetrexed plus best supportive care (BSC) and 27 (15.0%) patients randomised to placebo plus BSC had a protocol deviation. Table 7 in the ERG report summarises the protocol deviations that occurred. Levels of protocol deviations were low and most were comparable across the two treatment arms and so this is not of great concern to the ERG.</p>
<p><em>PARAMOUNT Trial Description and Critique of the Statistical Approach</em></p>
<p>The PARAMOUNT trial consisted of two phases; the first phase was a non-randomised induction phase and the second was a double-blind randomised maintenance phase.</p>
<p>According to the published paper and the statistical analysis plan (SAP), patients were randomised (2:1) to receive treatment using a computer generated random sequence with a block size of three. The trial report states that the &quot;randomisation ratio was chosen to provide sufficient comparative data to show the superiority of pemetrexed plus BSC while reducing patient exposure to the potentially inferior treatment of placebo plus BSC.&quot; Randomisation was stratified with the following baseline and prognostic factors:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Eastern Cooperative Oncology Group (ECOG) performance status just before randomisation (0 vs 1) </li>
    <li>Tumour response to induction chemotherapy (CTX) (complete or partial response vs stable disease) </li>
    <li>Disease stage before administration of induction therapy (IIIB vs IV) </li>
</ul>
<p>In the published paper it is stated that randomisation was done using the Pocock and Simon minimisation method; however the ERG found no mention of minimisation in other documents that described the PARAMOUNT trial methodology. In their clarification response to the ERG, the manufacturer stated that minimisation was not used. The ERG is unclear as to why the main published report of the trial refers to the Simon and Pocock minimisation method but is satisfied with the method of randomisation.</p>
<p><span style=&quot;text-decoration: underline;&quot;>Statistical Analyses</span></p>
<p>According to the manufacturer's submission (MS), the analysis population for primary and secondary efficacy analyses was the intention-to-treat (ITT) population, defined as all patients randomised to maintenance treatment, whether or not study treatment was received, analysed according to the treatment assigned at randomisation. The analysis population for the safety analysis was all patients enrolled in the study that were treated with at least one dose of pemetrexed plus cisplatin during the induction phase.</p>
<p>The statistical methods used to analyse the efficacy outcomes in the PARAMOUNT trial are presented in Table 10 in the ERG report. The ERG is satisfied that in the main, these methods of analysis are appropriate, however the ERG notes that in the MS p-values are reported in relation to adverse events (AEs), suggesting that hypothesis tests were performed although no formal statistical analysis of AEs was specified in the SAP.</p>
<p>See Section 4 in the ERG report for additional information on the statistical analyses (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><span style=&quot;text-decoration: underline;&quot;>Meta-analysis</span></p>
<p>As only one RCT investigating the efficacy of pemetrexed is available, it was not possible to perform a meta-analysis.</p>
<p>See Section 4 in the ERG report for additional information on clinical effectiveness analysis (see the &quot;Availability of Companion Documents&quot; field).</p>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Cost-effectiveness</span></strong></p>
<p><strong>Summary and Critique of Manufacturer's Review of Cost-effectiveness Evidence</strong></p>
<p><em>Model Structure</em></p>
<p>A schematic of the manufacturer's model is shown in Figure 3 in the ERG report. It comprises three health states: pre-progression, post-progression and dead. All patients enter the model in the pre-progression health state following a course of pemetrexed plus cisplatin CTX. At the beginning of each time period patients can either remain in the same health state or progress to a 'worse' health state, i.e., move from pre-progression to post-progression or dead; or move from post-progression to dead.</p>
<p>The resource use and utilities applied in the pre-progression health state relate to the maintenance phase of treatment. The post-progression health state corresponds with National Health Service (NHS) clinical practice following disease progression, representing the time period after maintenance treatment until death. On entering this state clinicians and patients reassess treatment options and a patient may be offered second-line treatment.</p>
<p>Variants of this model structure have been used frequently in the modelling of metastatic oncology for NICE Single Technology Appraisals (STAs).</p>
<p>The model has been developed in Microsoft Excel and has a 21-day cycle length. It employs a continuity correction and the base-case time horizon is 15.99 years. A discount rate of 3.5% has been used for both costs and outcomes and the perspective is stated to be that of the NHS and Personal Social Services.</p>
<p>See Section 5 in the ERG report for more information on the cost-effectiveness analysis (see the &quot;Availability of Companion Documents&quot; field).</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Considerations</strong></p>
<p>Technology appraisal recommendations are based on a review of clinical and economic evidence.</p>
<p><strong>Technology Appraisal Process</strong></p>
<p>The National Institute for Health and Care Excellence (NICE) invites 'consultee' and 'commentator' organisations to take part in the appraisal process. Consultee organisations include national groups representing patients and carers, the bodies representing health professionals, and the manufacturers of the technology under review. Consultees are invited to submit evidence during the appraisal and to comment on the appraisal documents.</p>
<p>Commentator organisations include manufacturers of the products with which the technology is being compared, the National Health Service (NHS) Quality Improvement Scotland and research groups working in the area. They can comment on the evidence and other documents but are not asked to submit evidence themselves.</p>
<p>NICE then commissions an independent academic centre to review published evidence on the technology and prepare an 'assessment report'. Consultees and commentators are invited to comment on the report. The assessment report and the comments on it are then drawn together in a document called the evaluation report.</p>
<p>An independent Appraisal Committee then considers the evaluation report. It holds a meeting where it hears direct, spoken evidence from nominated clinical experts, patients and carers. The Committee uses all the evidence to make its first recommendations, in a document called the 'appraisal consultation document' (ACD). NICE sends all the consultees and commentators a copy of this document and posts it on the NICE Web site. Further comments are invited from everyone taking part.</p>
<p>When the Committee meets again it considers any comments submitted on the ACD; then it prepares its final recommendations in a document called the 'final appraisal determination' (FAD). This is submitted to NICE for approval.</p>
<p>Consultees have a chance to appeal against the final recommendations in the FAD. If there are no appeals, the final recommendations become the basis of the guidance that NICE issues.</p>
<p><strong>Who Is on the Appraisal Committee?</strong></p>
<p>NICE technology appraisal recommendations are prepared by an independent committee. This includes health professionals working in the NHS and people who are familiar with the issues affecting patients and carers. Although the Appraisal Committee seeks the views of organisations representing health professionals, patients, carers, manufacturers and government, its advice is independent of any vested interests.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong><span style=&quot;text-decoration: underline;&quot;>Summary of Appraisal Committee's Key Conclusions</span></strong></p>
<p><strong>Availability and Nature of Evidence</strong></p>
<p>The manufacturer submitted a state-transition Markov model to evaluate the cost-effectiveness of pemetrexed compared with placebo.</p>
<p><strong>Uncertainties Around and Plausibility of Assumptions and Inputs in the Economic Model</strong></p>
<p>The Committee was not persuaded by the manufacturer's approach to the modelling of progression-free survival and overall survival.</p>
<p>The Committee also concluded that more accurate estimates of resource use and utility parameters were available than those used in the manufacturer's revised base case.</p>
<p><strong>Incorporation of Health-Related Quality-of-Life Benefits and Utility Values. Have Any Potential Significant and Substantial Health-Related Benefits Been Identified That Were Not Included in the Economic Model, and How Have They Been Considered?</strong></p>
<p>Patients in PARAMOUNT were asked to rate their health condition using the EuroQol 5D (EQ-5D). The manufacturer noted that the trial data did not provide values suitable for the pre- and post-progression health states, therefore a mixed regression analysis was carried out.</p>
<p>No significant and substantial health-related benefits that have not been captured by the quality adjusted life year (QALY) calculation were identified either in the submission or at the Committee meeting.</p>
<p><strong>Are There Specific Groups of People for Whom the Technology Is Particularly Cost Effective?</strong></p>
<p>No clinically relevant subgroups were identified during the appraisal.</p>
<p><strong>What Are the Key Drivers of Cost-effectiveness?</strong></p>
<p>The different approaches to estimating overall survival for the lifetime of the model between the manufacturer's updated revised base case (incremental cost-effectiveness ratios [ICERs] of &amp;pound;58,918 to &amp;pound;68,771 per QALY gained) and the Evidence Review Group's (ERG's) revised analysis (approximately &amp;pound;74,500 per QALY gained).</p>
<p><strong>Most Likely Cost-effectiveness Estimate (Given as an ICER)</strong></p>
<p>The Committee considered that the most plausible ICER was approximately &amp;pound;74,500 per QALY gained.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Consultee organisations from the following groups were invited to comment on the draft scope, Assessment Report and the Appraisal Consultation Document (ACD) and were provided with the opportunity to appeal against the Final Appraisal Determination.</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Manufacturer/sponsors </li>
    <li>Professional/specialist and patient/carer groups </li>
    <li>Commentator organisations (without the right of appeal) </li>
</ul>
<p>In addition, individuals selected from clinical expert and patient advocate nominations from the professional/specialist and patient/carer groups were also invited to comment on the ACD.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of evidence supporting the recommendations is not specifically stated.</p>
<p>The Appraisal Committee considered clinical and cost-effectiveness evidence submitted by the manufacturer of pemetrexed and a review of this submission by the Evidence Review Group.</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Appropriate use of pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer</p></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The Summary of Product Characteristics reports that the most common adverse reactions of pemetrexed are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis.</p>
<p>For full details of adverse reactions, see the Summary of Product Characteristics.</p></div>"/>
    </field>
  </section>
  <section secid="430" ordby="800" name="Contraindications">
    <field fieldid="144" ordby="805" id="431" name="Contraindications" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>For full details of contraindications, see the Summary of Product Characteristics.</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>This guidance represents the views of the National Institute for Health and Care Excellence (NICE) and was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. </li>
    <li>Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. </li>
</ul>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Mobile Device Resources"/>
      <fieldvalue value="Patient Resources"/>
      <fieldvalue value="Resources"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>National Institute for Health and Care Excellence. Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer. London (UK): National Institute for Health and Care Excellence; 2014 Apr. 45 p.&amp;nbsp;(Technology appraisal guidance; no. 309).&amp;nbsp;</td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2014 Apr"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>National Institute for Health and Care Excellence (NICE)</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Appraisal Committee</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Committee Members</em>: Professor Gary McVeigh (<em>Chair</em>), Professor of Cardiovascular Medicine, Queens University Belfast and Consultant Physician, Belfast City Hospital; Dr Lindsay Smith (<em>Vice Chair</em>), General Practitioner, West Coker Surgery, Somerset; Professor Darren Ashcroft, Professor of Pharmacoepidemiology, School of Pharmacy and Pharmaceutical Sciences, University of Manchester; Dr Aomesh Bhatt, Director of Regulatory and Medical Affairs, Europe and North America, Reckitt Benckiser; Dr Andrew Black, General Practitioner, Mortimer Medical Practice, Herefordshire; Professor David Bowen, Consultant Haematologist, Leeds Teaching Hospitals NHS Trust; Dr Matthew Bradley, Therapy Area Leader, Global Health Outcomes, GlaxoSmithKline; Dr Ian Campbell, Honorary Consultant Physician, Llandough Hospital, Cardiff; Professor Usha Chakravarthy, Professor of Ophthalmology and Vision Sciences, The Queen's University of Belfast; Professor Peter Clark, Consultant Medical Oncologist, Clatterbridge Centre for Oncology; Tracey Cole, Lay Member; Dr Ian Davidson, Senior Lecturer in Physiotherapy, Manchester Metropolitan University; John Dervan, Lay Member; Professor Simon Dixon, Professor of Health Economics, University of Sheffield; Dr Martin Duerden, Assistant Medical Director, Betsi Cadwaladr University Health Board, North Wales; Susan Dutton, Senior Medical Statistician, Oxford Clinical Trials Research Unit; Dr Alexander Dyker, Consultant Physician, Wolfson Unit of Clinical Pharmacology, University of Newcastle; Christopher Earl, Surgical Care Practitioner, Wessex Neurological Centre at Southampton University Hospital; Gillian Ells, Prescribing Advisor &amp;ndash; Commissioning, NHS Hastings and Rother and NHS East Sussex Downs and Weald; Professor Paula Ghaneh, Professor and Honorary Consultant Surgeon, University of Liverpool; Dr Susan Griffin, Research Fellow, Centre for Health Economics, University of York; Professor Carol Haigh, Professor in Nursing, Manchester Metropolitan University; Dr Paul Hepple, General Practitioner, Muirhouse Medical Group; Professor John Hutton, Professor of Health Economics, University of York; Professor Peter Jones, Emeritus Professor of Statistics, Keele University; Dr Steven Julious, Reader in Medical Statistics, University of Sheffield; Dr Tim Kinnaird, Lead Interventional Cardiologist, University Hospital of Wales, Cardiff; Warren Linley, Senior Research Fellow, Centre for Health Economics and Medicines Evaluation, Bangor University; Professor Jonathan Michaels, Professor of Clinical Decision Science, University of Sheffield; Dr Malcolm Oswald, Lay Member; Professor Femi Oyebode, Professor of Psychiatry and Consultant Psychiatrist, The National Centre for Mental Health; Dr John Radford, Director of Public Health, Rotherham Primary Care Trust and MBC; Dr Phillip Rutledge, GP and Consultant in Medicines Management, NHS Lothian; Dr Brian Shine, Consultant Chemical Pathologist, John Radcliffe Hospital, Oxford; Dr Murray Smith, Associate Professor in Social Research in Medicines and Health, University of Nottingham; Paddy Storrie, Lay Member; Dr Alison Talbot-Smith, Consultant in Public Health, Herefordshire Clinical Commissioning Group; Charles Waddicor, Chief Executive, NHS Berkshire West; Professor Carolyn Young, Consultant Neurologist, Walton Centre for Neurology and Neurosurgery</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Committee members are asked to declare any interests in the technology to be appraised. If it is considered there is a conflict of interest, the member is excluded from participating further in that appraisal.</p></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available from the <a href=&quot;http://www.nice.org.uk/Guidance/TA309&quot; title=&quot;National Institute for Health and Care Excellence (NICE) Web site&quot;>National Institute for Health and Care Excellence (NICE) Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following are available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous and non-small-cell lung cancer (TA309). Costing statement. London (UK): National Institute for Health and Care Excellence (NICE); 2014 Apr. 1 p. (Technology appraisal guidance; no. 309). Electronic copies: Available from the <a href=&quot;http://www.nice.org.uk/guidance/ta309/resources/lung-cancer-non-small-cell-non-squamous-pemetrexed-costing-statment&quot; title=&quot;National Institute for Health and Care Excellence (NICE) Web site&quot;>National Institute for Health and Care Excellence (NICE) Web site</a>. </li>
    <li>Greenhalgh J, Bagust A, Blundell M, Dwan K, Beale S, Davis H, Dundar Y, Vecchio F, Sacco J, Marshall E. Pemetrexed for maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small cell lung cancer. Liverpool (UK): LRiG, University of Liverpool; 2012. 75 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href=&quot;http://www.nice.org.uk/guidance/ta309/resources/lung-cancer-non-small-cell-non-squamous-pemetrexed-maintenance-following-pemetrexed-cisplatin-evidence-review-group-report2&quot; title=&quot;National Institute for Health and Care Excellence (NICE) Web site&quot;>NICE Web site</a>. </li>
</ul></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The following is available:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Pemetrexed as maintenance treatment for non-small-cell lung cancer after pemetrexed and cisplatin. Information for the public. London (UK): National Institute for Health and Care Excellence (NICE); 2014 Apr. (Technology appraisal guidance; no. 309). Electronic copies: Available from the <a href=&quot;http://www.nice.org.uk/guidance/TA309/InformationForPublic&quot; title=&quot;National Institute for Health and Care Excellence (NICE) Web site&quot;>National Institute for Health and Care Excellence (NICE) Web site</a>. Also available for download as an eBook or ePub from the <a href=&quot;http://www.nice.org.uk/guidance/TA309/InformationForPublic&quot; title=&quot;NICE Web site&quot;>NICE Web site</a>. </li>
</ul>
<p class=&quot;Disclaimer&quot;>Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on June 29, 2014.</p>
<p>The National Institute for Health and Care Excellence (NICE) has granted the National Guideline Clearinghouse (NGC) permission to include summaries of their Technology Appraisal guidance with the intention of disseminating and facilitating the implementation of that guidance. NICE has not verified this content to confirm that it accurately reflects the original NICE guidance and therefore no guarantees are given by NICE in this regard. All NICE technology appraisal guidance is prepared in relation to the National Health Service in England and Wales. NICE has not been involved in the development or adaptation of NICE guidance for use in any other country. The full versions of all NICE guidance can be found at <a href=&quot;http://www.nice.org.uk&quot; title=&quot;National Institute for Health and Care Excellence (NICE) Web site&quot;>www.nice.org.uk</a>.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <a href=&quot;/about/inclusion-criteria.aspx&quot;>http://www.guideline.gov/about/inclusion-criteria.aspx</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 21:22:59 Sep 30, 2016 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 00:13:46 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 155.873 (3)
  esindex: 0.007
  captures_list: 176.717
  CDXLines.iter: 14.081 (3)
  PetaboxLoader3.datanode: 45.32 (4)
  exclusion.robots: 0.334
  exclusion.robots.policy: 0.318
  RedisCDXSource: 3.113
  PetaboxLoader3.resolve: 229.303 (2)
  load_resource: 154.263
-->